Biomarker driven trials in the era of precision medicineThe benefits of this approach include the evaluation of a small number of patients per treatment, reduced costs, and rapid time to results and implementation across treatments and tumor types.
Patient enrollment in biomarker driven clinical trials is restricted to only biomarker-positive patients as ONCY is demonstrating with the Phase 2 Bracelet-1 breast cancer study where those patients who have been identified to respond to pelareorep + immune checkpoint inhibiton who have low levels of PD-1 were included in the trial.